Skip to main content

Stay up-to-date with SGD Pharma’s environmental, social and ethical efforts and download our latest annual CSR report

SGD Pharma takes its global and local responsibilities seriously and works consistently to be compliant with all environmental, social and ethical requirements. The publication of SGD Pharma’s 2022 sustainability report reinforces our company-wide commitment to a green and sustainable present and future.

Download the full report here.

 

Key highlights of SGD Pharma CSR report 2022:

  • 100% of all SGD Pharma owned glass manufacturing plants are ISO 45001 certified
  • 100% of SGD Pharma sites are certified with ISO 14001 
  • 100% of critical suppliers have CSR clauses in their contracts 
  • 99.5% of our internal cullet is reused in our production process 
  • >20% reduction in water consumption vs 2020
  • 86% EHS Maturity Matrix  

 

Zhanjiang China CSR spotlight – planting mangroves 

As well as being SA 8000 certified, the SGD Pharma China plant in Zhanjiang supports the local community by its local footprint, relationships with local government and institutions, local hiring policies and by helping to protect biodiversity in Zhanjiang. The city is home to one of the world’s most successful examples of wetland ecological restoration and SGD Pharma has committed to supporting the community’s efforts to tackle deforestation by planting mangrove trees.  

By the end of 2022, SGD Pharma employees planted a total of 1000 mangroves trees on the beach at Zhanjiang Nanshan Island, China, in association with Zhanjiang Nature and Resource Bureau and Guangdong Ocean University.

During a visit to the SGD Pharma Zhanjiang plant in April 2023, Mayor Zeng Jinze joined our CEO Olivier Rousseau to plant new mangrove roots and stressed the importance of mangrove preservation for Zhanjiang and the many benefits it brings to society in terms of biodiversity, carbon sync and protection of the coast. SGD Pharma is proud to contribute to biodiversity and will continue to support projects in China and other plants during 2023.  

 

 Mangrove plantation

 

Rating for sustainability

SGD Pharma has been awarded Gold EcoVadis rating for the year 2022, highlighting the actions we have implemented through our global CSR strategy to improve the way the business operates and how it treats both its employees and the environment.

We were proud to achieve our highest ever score of 75 out of 100, which places the company in the top 2% of global companies in the ‘Manufacture of glass and glass products’ category.

Download the full report here.

 

Next steps

The renewed company-wide focus on CSR means stretch targets have been set ahead:   These include:

  • Achieve Excellence rating in Quality Maturity Matrix by 2025 
  • Halve Scope 1 and Scope 2 emissions by 2030 
  • 35% reduction in carbon footprint by 2030 
  • 65% reduction in carbon footprint by 2040 (compared with 2020 baseline) 
  • Goal: Zero accidents